Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00041730

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00041730. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of Rituxan(R) Plus FavId(TM) (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients With Grade 1 or 2 Follicular B-Cell Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the ability of patients treated with Rituxan® plus FavId™ and GM-CSF to mount an immune response (humoral and/or cellular) to KLH and their idiotype.

Study identification

NCT ID: NCT00041730
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Favrille; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Non-Hodgkin's Lymphoma

Interventions

Id-KLH Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2002 (Type not available)
Primary completion: Not listed
Completion: Not listed
Last update posted: Sep 30, 2009

Started 2002

United States locations

U.S. sites: 15
U.S. states: 9
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of California, San Diego	La Jolla	California	92093	—
Tower Hematology Oncology Medical Group	Los Angeles	California	90048	—
Oncology Associates of San Diego	San Diego	California	92123	—
University California, San Francisco	San Francisco	California	94143	—
University of Florida, Jacksonville	Jacksonville	Florida	32209	—
H. Lee Moffitt Cancer Center	Tampa	Florida	33612	—
Northwestern University	Chicago	Illinois	60611	—
Ochsner Clinical Foundation	New Orleans	Louisiana	70121	—
Henry Ford Hospital	Detroit	Michigan	48202	—
New York Medical College - Our Lady of Mercy Medical Center, Comprehensive Cancer Center	The Bronx	New York	10466	—
Oncology/Hematology Care Clinical Cancer Institute	Cincinnati	Ohio	45219	—
University Hospitals of Cleveland Case Western, Ireland Cancer Center	Cleveland	Ohio	44106	—
The Ohio State University	Columbus	Ohio	43210	—
The Sarah Cannon Cancer Center	Nashville	Tennessee	37203	—
University of Virginia	Charlottesville	Virginia	22902	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00041730, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 30, 2009 · Synced Nov 14, 2026